On March 21, 2017 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reported a poster titled "Intratumoral Electroporation-mediated IL-12 Gene Therapy Can Enhance Tumor Immunogenicity" (Poster #2074), at the Keystone Symposia Conference, "Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology," in Whistler, British Columbia, Canada (Press release, OncoSec Medical, MAR 21, 2017, View Source [SID1234518230]). The poster included preclinical data demonstrating that in vivo electroporation of intratumoral plasmid IL-12 (ImmunoPulse IL-12) enhances immunogenicity in poorly immunogenic mouse cancer models. For more information about this meeting, please visit View Source Schedule your 30 min Free 1stOncology Demo! "These data support the hypothesis that intratumoral delivery of plasmid IL-12 with electroporation can alter the tumor’s immune environment in such a way that a ‘cold’ non-immunogenic tumor is converted to a ‘hot’ immunogenic tumor, thus further supporting recent clinical data that ImmunoPulse IL-12 is a rational combination therapy with anti-PD-1 checkpoint therapies," said Punit Dhillon, President and CEO. "Also, generation of an antigen-specific CD8 T-cell response provides evidence for a potential mechanism of action for the abscopal responses seen in both preclinical and clinical settings."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The full-text abstract is available on the Publications section of OncoSec’s website (www.oncosec.com).